GDF15 and non-small cell lung carcinoma: To explore whether the relationship between increased circulating GDF15 and the development of CAC was restricted to early-stage NSCLC, we measured plasma GDF15 levels in 164 patients with stage IV lung adenocarcinoma in an independent cohort of patients with metastatic NSCLC (NCT01360554)50.